Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1931 1
1949 3
1950 1
1951 2
1952 2
1953 2
1954 2
1955 1
1957 1
1958 1
1959 2
1960 1
1964 1
1966 1
1967 1
1968 1
1971 1
1972 1
1976 3
1977 2
1979 1
1981 1
1982 1
1984 3
1985 2
1986 5
1987 6
1988 8
1989 3
1990 3
1991 4
1992 2
1993 3
1994 1
1995 1
1996 5
1997 4
1998 6
1999 4
2000 5
2001 4
2002 4
2003 9
2004 4
2005 4
2006 6
2007 5
2008 6
2009 4
2010 3
2011 5
2012 6
2013 3
2014 4
2015 3
2016 7
2017 9
2018 4
2019 7
2020 2
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

188 results
Results by year
Filters applied: . Clear all
Page 1
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce.
Kluger HM, Tawbi HA, Ascierto ML, Bowden M, Callahan MK, Cha E, Chen HX, Drake CG, Feltquate DM, Ferris RL, Gulley JL, Gupta S, Humphrey RW, LaVallee TM, Le DT, Hubbard-Lucey VM, Papadimitrakopoulou VA, Postow MA, Rubin EH, Sharon E, Taube JM, Topalian SL, Zappasodi R, Sznol M, Sullivan RJ. Kluger HM, et al. Among authors: rubin eh. J Immunother Cancer. 2020 Mar;8(1):e000398. doi: 10.1136/jitc-2019-000398. J Immunother Cancer. 2020. PMID: 32238470 Free PMC article.
Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology.
Hobbs BP, Barata PC, Kanjanapan Y, Paller CJ, Perlmutter J, Pond GR, Prowell TM, Rubin EH, Seymour LK, Wages NA, Yap TA, Feltquate D, Garrett-Mayer E, Grossman W, Hong DS, Ivy SP, Siu LL, Reeves SA, Rosner GL. Hobbs BP, et al. Among authors: rubin eh. J Natl Cancer Inst. 2019 Feb 1;111(2):118-128. doi: 10.1093/jnci/djy196. J Natl Cancer Inst. 2019. PMID: 30561713 Free PMC article. Review.
A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer.
Oza AM, Estevez-Diz M, Grischke EM, Hall M, Marmé F, Provencher D, Uyar D, Weberpals JI, Wenham RM, Laing N, Tracy M, Freshwater T, Lee MA, Liu J, Qiu J, Rose S, Rubin EH, Moore K. Oza AM, et al. Among authors: rubin eh. Clin Cancer Res. 2020 Sep 15;26(18):4767-4776. doi: 10.1158/1078-0432.CCR-20-0219. Epub 2020 Jul 1. Clin Cancer Res. 2020. PMID: 32611648
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.
Moschos SJ, Sullivan RJ, Hwu WJ, Ramanathan RK, Adjei AA, Fong PC, Shapira-Frommer R, Tawbi HA, Rubino J, Rush TS 3rd, Zhang D, Miselis NR, Samatar AA, Chun P, Rubin EH, Schiller J, Long BJ, Dayananth P, Carr D, Kirschmeier P, Bishop WR, Deng Y, Cooper A, Shipps GW, Moreno BH, Robert L, Ribas A, Flaherty KT. Moschos SJ, et al. Among authors: rubin eh. JCI Insight. 2018 Feb 22;3(4):e92352. doi: 10.1172/jci.insight.92352. eCollection 2018 Feb 22. JCI Insight. 2018. PMID: 29467321 Free PMC article. Clinical Trial.
Optimal two-stage designs for exploratory basket trials.
Zhou H, Liu F, Wu C, Rubin EH, Giranda VL, Chen C. Zhou H, et al. Among authors: rubin eh. Contemp Clin Trials. 2019 Oct;85:105807. doi: 10.1016/j.cct.2019.06.021. Epub 2019 Jun 29. Contemp Clin Trials. 2019. PMID: 31260789
188 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page